← Ablatotech Vitals
Rheumatology EvidenceDigest

Efficacy of Novel Therapies for Managing Refractory Inflammatory Myopathy-Associated Interstitial Lung Disease

Rheumatology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 20, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Refractory interstitial lung disease (ILD) associated with idiopathic inflammatory myopathies (IIM) remains a significant cause of morbidity and mortality. Emerging evidence supports the cautious use of novel therapies including rituximab, antifibrotics such as nintedanib, and calcineurin inhibitors like tacrolimus in select patients who fail conventional immunosuppression. While these agents show promise in stabilizing or improving lung function, data remain limited by small cohorts and heterogeneous study designs. Clinicians should individualize treatment decisions, balancing potential benefits against safety profiles and patient-specific factors.

Clinical bottom line

Refractory interstitial lung disease (ILD) associated with idiopathic inflammatory myopathies (IIM) remains a significant cause of morbidity and mortality. Emerging evidence supports the cautious use of novel therapies including rituximab, antifibrotics such as nintedanib, and calcineurin inhibitors like tacrolimus in select patients who fail conventional immunosuppression. While these agents show promise in stabilizing or improving lung function, data remain limited by small cohorts and heterogeneous study designs. Clinicians should individualize treatment decisions, balancing potential benefits against safety profiles and patient-specific factors.

What the evidence shows

Recent studies highlight rituximab as a potentially effective option for refractory IIM-associated ILD. Jang et al. (2023) reported improved lung function trajectories and stabilization of forced vital capacity (FVC) in patients treated with rituximab, with a favorable safety profile in a case series and conference abstract. These findings suggest B-cell depletion may modulate disease activity in this subgroup.

Antifibrotic therapy, particularly nintedanib, has gained attention for its role in progressive fibrosing ILD phenotypes. Wilfong et al. (2021) reviewed the application of antifibrotics in IIM-ILD, noting that nintedanib slowed decline in lung function in clinical trials of fibrosing ILDs, including connective tissue disease-associated ILD. Liang et al. (2020) provided early data on nintedanib’s tolerability and efficacy specifically in IIM-ILD, supporting its use as adjunctive therapy in refractory cases.

Calcineurin inhibitors, especially tacrolimus, have demonstrated efficacy in IIM-ILD management. Gordon et al. (2014) identified tacrolimus responders and defined its role in stabilizing lung disease, particularly when combined with corticosteroids and other immunosuppressants. This agent remains a cornerstone in many treatment algorithms.

Quantitative thoracic imaging advances, as described by Qiang et al. (2025), offer improved phenotypic stratification and monitoring of IIM-ILD subtypes, potentially guiding therapeutic choices and assessing response to novel agents.

Poirier-Blanchette et al. (2026) provide a comprehensive review of novel therapies for refractory IIM-ILD, emphasizing the need for further controlled studies to validate efficacy and safety while highlighting current clinical experience with these agents.

Caveats and uncertainty

Most evidence derives from observational studies, case series, and small trials with heterogeneous patient populations and variable definitions of refractory disease. Randomized controlled trials specifically targeting IIM-ILD are scarce, limiting definitive conclusions on comparative efficacy.

Safety data, particularly long-term, remain incomplete. Rituximab’s immunosuppressive effects raise infection risk concerns, and antifibrotics can cause gastrointestinal and hepatic adverse events. Tacrolimus requires monitoring for nephrotoxicity and neurotoxicity.

Heterogeneity in IIM subtypes, ILD patterns, and disease severity complicates generalizability. Biomarkers predicting response to these novel therapies are under investigation but not yet established in clinical practice.

Imaging modalities and quantitative assessments, while promising, require standardization and validation before routine integration into treatment algorithms.

How this may change practice

Clinicians managing refractory IIM-ILD should consider integrating rituximab and antifibrotic agents like nintedanib into treatment regimens, especially for patients with progressive fibrosing phenotypes unresponsive to conventional immunosuppression. Tacrolimus remains a valuable option, particularly in combination therapy.

Multidisciplinary collaboration involving rheumatology, pulmonology, and radiology is essential to optimize diagnosis, monitoring, and therapeutic decisions. Quantitative imaging may enhance personalized treatment approaches as evidence evolves.

Given current limitations, treatment should be individualized, with careful assessment of risks and benefits, and patients should be counseled on the experimental nature of some therapies. Enrollment in clinical trials is encouraged to advance evidence.


References

  1. Poirier-Blanchette L, et al. Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease. Curr Opin Rheumatol 2026. DOI:10.1097/bor.0000000000001194
  2. Liang J, et al. Investigating the efficacy and tolerability of nintedanib therapy in idiopathic-inflammatory-myopathy-related interstitial lung disease. http://isrctn.com/ 2020. DOI:10.1186/isrctn10507540 [link]
  3. Jang Y, et al. Rituximab Improves Lung Function Decline in Patients With Idiopathic Inflammatory Myopathy-associated Interstitial Lung Disease. A39. MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES. 2023. DOI:10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1523
  4. Jang Youngeun, et al. The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series. J Clin Med 2023;12:3406. DOI:10.3390/jcm12103406
  5. Qiang Y, et al. Longitudinal quantitative thoracic imaging in idiopathic inflammatory myopathy-associated interstitial lung disease: phenotypic dynamics and subtype stratification. ILD/DPLD of known origin. 2025. DOI:10.1183/13993003.congress-2025.pa6109
  6. Gordon P, et al. Tacrolimus in idiopathic inflammatory myopathy-associated interstitial lung disease: defining roles and responders. Rheumatology 2014;53:2205–2212. DOI:10.1093/rheumatology/keu335
  7. Wilfong EM, et al. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis 2021;13:1759720X211060907. DOI:10.1177/1759720x211060907

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team